Table 4 OAV replication is controlled by cellular promoters

Bladder cancer

E2F1

CG0070

Ad5-E2F-E1A-GM-CSF

GM-CSF

Intravesical

Phase III

NCT04452591

[111]

N-dodecyl-B-D-maltoside

Melanoma

ICOVIR-5

Ad5-E2F-∆24-RGD4C

Intravenous

Phase I

NCT01864759

[119]

Solid tumor

ICOVIR-7

Ad5-E2F-palin-∆24-RGD4C

E2F palindromes

Intravenous

Preclinical

[120]

Solid tumor

ICOVIR-15K-cBiTE

Ad5-E2F-∆24-RGD4C-cBiTE

EGFR-targeting-BiTE

Intratumoral

Preclinical

[121]

PBMC or T cells

Solid tumor

VCN-01

Ad5-E2F-∆24-RGDK-PH20

PH20

Intravenous

Phase I

NCT02045602

[122]

Nab-paclitaxel, gemcitabine

Pancreatic cancer

Intratumoral

Phase I

NCT02045589

[123]

Gemcitabine, abraxane

Solid tumor

VCN-11

Ad5-E2F-∆24-RGDK-PH20-ABD

PH20, albumin-binding domain (ABD)

Intravenous

Preclinical

[124]

Liver cancer

hTERT

OBP-301

Ad5-hTERT-E1A-IRES-E1B

Intratumoral

Phase I

NCT02293850

[116]

Esophageal cancer

Phase I

NCT03213054

[125]

Radiotherapy

Solid tumor

Phase I

NCT03172819

Pembrolizumab

Bone and soft tissue sarcomas

OBP-405

Ad5-hTERT-E1A-IRES-E1B-RGD

Intratumoral

Preclinical

[118]

Pancreatic cancer

OBP-502

Ad5-hTERT-E1A-IRES-E1B-RGD-p53

p53

Intratumoral

Preclinical

[126]

Anti-PD-1 monotherapy

Pancreatic cancer

OBP-702

Ad5-hTERT-E1A-IRES-E1B-RGD-p53

p53

Intratumoral

Preclinical

[127]

Anti-PD-L1 monotherapy

Solid tumor

Ad3-hTERT-E1A

Preclinical

[128]

Chemotherapy

Prostate cancer

Ad3-hTERT-CMV-CD40L

CD40L

Preclinical

[114]

Solid tumor

KGHV500

Ad5-hTERT-E1A-IRES-E1B-RGD

anti-p21Ras scFv

Preclinical

[129]

Liver cancer

AFP

SynOV1.1

Ad5-AFP-∆24-RGD-GM-CSF

GM-CSF

Intratumoral

Phase I

NCT04612504

Ad5-AFP-NOS- 3/RSV

Nitric Oxide Synthase Type III (NOS-3)

Intravenous

Preclinical

[130]